Trial reportCancer immunology, immunotherapy : CII2011
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
Trial report in Cancer immunology, immunotherapy : CII, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00060528 (A Phase I/II Pilot Study of Sequential Vaccinations With rFowlpox-PSA), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Pilot Study of Sequential Vaccinations With rFowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM) Alone, or in Combination With rVaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM), and the Role of GM-CSF, in Men With Prostate Cancer
Who cites it
31 citing papers in PubMed, 55 citations in OpenAlex.
- Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.Journal for immunotherapy of cancer · 2020Trial
- Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.Cancer prevention research (Philadelphia, Pa.) · 2015Trial
- Trial
- A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.Cancer immunology, immunotherapy : CII · 2014Trial
- Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.Cancer immunology research · 2014Trial
- mRNA cancer vaccines: Advances, trends and challenges.Acta pharmaceutica Sinica. B · 2022Review
- Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.Journal of personalized medicine · 2021Review
- The immune system in cancer metastasis: friend or foe?Journal for immunotherapy of cancer · 2017Review
- The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy.Oncoimmunology · 2016Article
- The evolving role of immunotherapy in prostate cancer.Current opinion in oncology · 2016Review
- Integrating Immunotherapies in Prostate Cancer.Current oncology reports · 2015Review
- p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.Cancer immunology, immunotherapy : CII · 2014Article
- Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.Journal for immunotherapy of cancer · 2014Article
- Effects of conventional therapeutic interventions on the number and function of regulatory T cells.Oncoimmunology · 2013Article
- Dramatic and prolonged PSA response after retreatment with a PSA vaccine.Clinical genitourinary cancer · 2013Article
- Immunotherapy and immune evasion in prostate cancer.Cancers · 2013Article
- Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.Journal of translational medicine · 2013Article
- Monitoring regulatory immune responses in tumor immunotherapy clinical trials.Frontiers in oncology · 2013Article
- Therapeutic cancer vaccines: past, present, and future.Advances in cancer research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
We have previously shown that the suppressive function of regulatory T cells (Tregs) from peripheral blood mononuclear cells (PBMCs) is enhanced in patients with prostate cancer when compared with healthy individuals. Two phase II studies using the PSA-TRICOM vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) showed evidence of patient benefit in terms of enhanced survival. The Halabi nomogram has been used to predict survival (HPS) of patients with mCRPC treated with conventional chemotherapy or second-line hormonal therapy. Tregs from PBMCs of patients (n = 23) with mCRPC were obtained pre- and post-three monthly vaccinations, and analyzed for number, phenotype, and suppressive function. Changes post- versus pre-vaccination in these parameters were compared with 3-year survival and HPS. No differences in Treg numbers were observed post- versus pre-vaccination. Trends (P = 0.029) were observed between overall survival (OS) and a decrease in Treg suppressive function post- versus pre-vaccination. Trends were also observed in analyzing effector:Treg (CD4(+)CD25(+)CD127(-)FoxP3(+)CTLA4(+)) ratio post- versus pre-vaccination with OS versus HPS. These data provide preliminary evidence for a possible association between improved OS and a decrease in Treg function when PBMCs are analyzed after three monthly vaccinations. Patients with an OS > HPS were more likely to have decreased Treg function following vaccine. Larger studies to confirm and extend these findings are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.